Skip to main content
TipRanks
Go Ultimate75% OFF

FluoGuide A/S (FLUO) AI Stock Analysis

1 Followers
SE:FLUO

FluoGuide A/S

(Nasdaq OMX AB:FLUO)

Select Model
Rating:41Neutral
Price Target:SEK 28.00▼(-3.11% Downside)
Action:reiterated
Date:08/27/26

The score is held down primarily by very weak financial performance—minimal revenue, large ongoing losses, and heavy cash burn—along with rising leverage. Technicals add further pressure as the stock trades below major moving averages with negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and there is no dividend yield data.

Positive Factors
Focused oncology imaging platformFG001 targets a clear surgical need: improving tumor visualization while sparing healthy structures. If development and approval succeed, this focused platform could support product sales and licensing, creating more than one route to future commercialization.
Negative Factors
Minimal and declining revenueRevenue remains negligible and has declined sharply, while the company continues to report a very large net loss. The gap between current commercial scale and the cost base indicates substantial execution risk before the pipeline can generate meaningful recurring revenue.

FluoGuide A/S (FLUO) vs. iShares MSCI Sweden ETF (EWD)

-40%-30%-20%-10%0%10%20%SE:FLUO-32.32%EWD+14.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 472.49M
Dividend Yield
―
Average Volume (3M)
4,925
Price to Earnings (P/E)
-6.5
Beta (1Y)
0.16
Revenue Growth
―
EPS Growth
-23.57%
Country
Sweden
Employees
7
Sector
General
Sector Strength
55
Industry
Biotechnology

FluoGuide A/S Business Overview & Revenue Model

Company Description

FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade g...

How the Company Makes Money

FluoGuide’s business model is centered on developing proprietary fluorescence imaging agents and monetizing them through (1) future commercial sales (if/when regulatory approvals are obtained) and/or (2) partnering and licensing transactions with lar...

FluoGuide A/S Financial Statement Overview

Summary

Overall financial quality is weak: revenue is minimal and declining, losses are very large with deeply negative margins, and operating/free cash flow show heavy ongoing cash burn. The balance sheet still has positive equity, but leverage has risen to near parity with equity, reducing flexibility if losses persist.

Income Statement

9Very Negative

Balance Sheet

38Negative

Cash Flow

14Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue54.00K0385.00K423.00K6.51M9.61M
Gross Profit-416.92K-571.17K385.00K423.00K6.51M9.61M
EBITDA-48.08M-40.42M-32.58M-43.66M-32.21M-28.65M
Net Income-46.24M-40.39M-28.96M-38.38M-27.34M-23.77M
Balance Sheet
Total Assets65.25M88.34M28.38M29.61M35.62M53.31M
Cash, Cash Equivalents and Short-Term Investments49.92M78.84M18.61M21.67M26.01M46.76M
Total Debt27.56M28.30M624.00K10.83M205.00K57.00K
Total Liabilities34.51M33.78M5.31M16.89M3.65M14.61M
Stockholders Equity30.74M54.56M23.07M12.72M31.97M38.70M
Cash Flow
Free Cash Flow-44.28M-37.83M-30.00M-31.81M-37.71M-15.06M
Operating Cash Flow-43.80M-37.83M-29.15M-31.81M-37.65M-15.06M
Investing Cash Flow-30.37M-30.61M-987.00K-37.00K-117.00K0
Financing Cash Flow74.76M99.33M27.08M27.50M17.02M51.18M

FluoGuide A/S Technical Analysis

Technical Analysis SentimentNegative
Last Price28.90

Price Trends

50DMA32.58Negative
100DMA33.46Negative
200DMA36.25Negative

Market Momentum

MACD-0.82Positive
RSI37.78Neutral
STOCH14.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLUO, the sentiment is Negative. The current price of 28.90 is below the 20-day moving average (MA) of 30.41, below the 50-day MA of 32.58, and below the 200-day MA of 36.25, indicating a bearish trend. The MACD of -0.82 indicates Positive momentum. The RSI at 37.78 is Neutral, neither overbought nor oversold. The STOCH value of 14.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:FLUO.

FluoGuide A/S Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:FLUO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:FLUISE:FLUI58NeutralSEK 37.78M13.9921.37%―837.37%―
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:ONCOSE:ONCO46NeutralSEK 772.99M-2.79――65.37%43.28%
SE:BINVSE:BINV43NeutralSEK 201.36M-0.41-128.54%―-83.67%-50.29%
SE:SPAGOSE:SPAGO43NeutralSEK 34.97M-1.17-87.37%―-97.52%31.31%
SE:BIOVIC.BSE:BIOVIC.B41NeutralSEK 89.52M-1.30-75.51%―56.06%63.95%
SE:FLUOSE:FLUO41NeutralSEK 480.67M-6.51―――-23.57%

* General Sector Average

Performance Comparison

0%100%200%300%SE:FLUOSE:BINVSE:ONCOSE:BIOVIC.BSE:SPAGOSE:FLUIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:FLUO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:FLUOFluoGuide A/S28.90-14.80-33.87%
SE:BINVBioInvent International AB3.02-28.18-90.32%
SE:ONCOOncopeptides AB1.76-3.45-66.21%
SE:BIOVIC.BBiovica International AB Class B0.32-0.25-43.36%
SE:SPAGOSpago Nanomedical AB0.05-0.07-59.29%
SE:FLUIFluicell AB28.6015.30115.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 27, 2026